Smarti

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Smarti

What is Smarti? An Overview

The drug Smarti is a brand name for a specialized prescription-only medicine used as part of a long-term strategy to manage chronic allergic inflammation and related respiratory issues. Its core identity is defined by its primary active ingredient, montelukast sodium, but the most recognized market variation, Smarti-M, is a fixed-dose combination product.

Property Description
Active ingredient Montelukast (as montelukast sodium)
Form Tablet, Chewable Tablet, Oral Granules
Pharmacological class Leukotriene Receptor Antagonist (LTRA)
General Use (Rx Status) Long-term control; Prescription-only medicine
Origin Synthetic compound

Defining the Pharmacological Class and Unique Composition

Smarti is classified as a Leukotriene Receptor Antagonist (LTRA), a group of synthetic medicines primarily defined by the action of montelukast sodium. This class of drugs is clinically recognized for its role in modifying the inflammatory cascade, providing a sustained foundational action against chronic allergic processes. A key differentiating factor is the Smarti-M version, a combination product that integrates rupatadine, an antihistamine, alongside montelukast. This dual composition allows the medication to target two distinct inflammatory mediators—leukotrienes and histamine—making it useful for patients experiencing both chronic inflammation and common allergic symptoms.


Forms, Delivery, and General Purpose

The medication is designed for oral administration and is supplied in multiple solid drug forms, including film-coated tablets and chewable tablets. This variety facilitates consistent daily dosing across various patient groups, notably making it easier for pediatric patients who may require the chewable tablet form. The overall general purpose of Smarti is to provide stability and long-term control. It achieves this by implementing a selective chemical blockade against inflammatory substances called cysteinyl leukotrienes at the CysLT1 receptor, thereby helping to reduce chronic underlying inflammation and maintain open airways.

Regulatory References

  1. FDA-Approved Drug Label for Montelukast Sodium

What side effects are possible with Smarti?

Possible Side Effects and Safety Information

The safety profile of Smarti, which contains montelukast and may include rupatadine, is officially classified by regulatory authorities based on the body systems affected and the frequency of occurrence. Documented adverse reactions range across multiple System-Organ Classes (SOC), including Gastrointestinal, Nervous System, and Psychiatric Disorders.

Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their incidence reported in clinical trials and post-marketing data:

Classification Examples of Reactions
Very Common Upper respiratory tract infection (montelukast)
Common Headache, somnolence, dizziness, fatigue, dry mouth, diarrhoea, nausea, vomiting
Uncommon Insomnia, seizures, epistaxis, urticaria, oedema

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight a risk of serious neuropsychiatric events associated with montelukast, which include agitation, depression, and reports of suicidal thoughts and behaviour. Furthermore, in rare cases, patients may exhibit symptoms consistent with Churg-Strauss Syndrome (a form of vasculitis), sometimes linked to the reduction of concurrent oral corticosteroid therapy.

Specific safety considerations exist for certain populations. Pediatric patients have a reported increased incidence of elevated liver enzymes. Use is restricted for individuals with known hypersensitivity to the active ingredients. Caution is advised concerning severe hepatic impairment and the potential for increased exposure to rupatadine when combined with specific enzyme inhibitors, thereby increasing the risk of adverse reactions.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation defines the overdose profile of Smarti based on the documented manifestations of its components.

Overdose Scope

Category Documented Manifestations/Actions
Documented Presentations Symptoms may include somnolence, headache, vomiting, abdominal pain, tachycardia, and psychomotor hyperactivity (agitation).
Severe Outcomes Reported severe manifestations include the risk of Torsade de pointes (a ventricular arrhythmia), severe neuropsychiatric events (e.g., suicidal thoughts/behavior), and systemic eosinophilia/vasculitis.
Immediate Action Seek immediate medical attention following any suspected overdose. Discontinuation and immediate contact with a healthcare provider are mandated if serious neuropsychiatric changes are observed.

Official Overdose Statements

  • No specific antidote is known for Smarti overdose.
  • Management is limited to symptomatic and supportive treatment and continuous clinical monitoring.
  • Medical monitoring is required for patients with pre-existing impaired renal or hepatic functions.
  • Overdose has been formally reported in pediatric patients.

Connection to the Overall Overdose Profile

Regulatory documents require immediate action due to the potential for severe cardiac and neuropsychiatric outcomes. Because no specific antidote exists, the official procedure mandates supportive care and close clinical observation until the clinical status stabilizes. This structure ensures clarity on the necessary urgent steps and required monitoring conditions.

Therapeutic Uses of Smarti

Main Therapeutic Uses

Smarti is primarily utilized for the management of specific cognitive and neurological conditions. Its pharmacological profile is designed to assist in stabilizing neurotransmitter activity, which plays a critical role in how the brain processes information and maintains focus.

Primary Indications

  • Cognitive Support: It is frequently prescribed to address deficits in attention and executive function. By modulating chemical signaling in the brain, it helps individuals maintain alertness and cognitive clarity.
  • Neurological Regulation: In certain clinical contexts, it is used to manage symptoms associated with sleep-wake cycle disruptions, helping to promote wakefulness during daytime hours.
  • Executive Function Enhancement: The medication is indicated for improving the ability to organize tasks, manage time, and sustain mental effort over extended periods.

Clinical Benefits

The benefits of Smarti are observed through its impact on daily functional capabilities and mental performance. While individual responses vary, the general therapeutic goals include:

Improved Attention Span

One of the central benefits is the increased ability to focus on specific tasks without being easily diverted by external stimuli. This stabilization of attention is often a primary goal of treatment.

Enhanced Mental Processing

Users may experience a more streamlined thought process. This includes a reduction in mental fatigue and an improved capacity to handle complex information-heavy tasks that require sustained cognitive endurance.

Behavioral Stability

By addressing underlying neurochemical imbalances, the medication can contribute to a more consistent mood and behavioral pattern, reducing the frequency of impulsive responses or cognitive fluctuations throughout the day.

Regulatory References

  1. NIH DailyMed Overview of Montelukast

Eligibility and Restrictions for Use

The use of Smarti (montelukast ± rupatadine) is governed by official regulatory criteria that specify eligible and restricted populations.

Populations for whom use is contraindicated

Contraindications include individuals with known hypersensitivity to montelukast, rupatadine, or any excipient. The medicine is also not indicated for the treatment of acute asthma attacks. Furthermore, the rupatadine component results in a specific contraindication for patients with severe hepatic impairment.

Age-related eligibility rules

Standard adult use is established for patients generally 15 years and older. Pediatric use is approved with specific formulations, such as chewable tablets, for chronic asthma and allergic rhinitis, but safety and effectiveness are not established in infants under six months of age. The combination product tablets are not recommended for children below 12 years.

Condition-specific eligibility rules

Use is not recommended in patients with severe renal impairment. Caution is advised for older adults and individuals with a history of seizures. Regarding Pregnancy and Lactation, use is generally not recommended, and a decision to discontinue the drug or breastfeeding is specified in official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions Potent CYP3A4 Inhibitors, CYP450 Inducers (e.g., Rifampin), other QTc-Prolonging Drugs, and CNS Depressants [Source 2.4, 3.1].
Specific interacting medicines (if explicitly listed) Potent Inhibitors: Ketoconazole, Itraconazole, Clarithromycin (avoidance advised/contraindicated) [Source 3.1, 3.4]. Moderate Inhibitor: Erythromycin (use with caution) [Source 3.3]. Other: Gemfibrozil (increases Montelukast exposure) [Source 1.2].
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic Interaction: Inhibition of Cytochrome P450 3A4 (Rupatadine pathway) resulting in increased systemic exposure [Source 3.1]. Inhibition of CYP2C8 by Gemfibrozil resulting in significantly increased Montelukast systemic exposure [Source 4.4]. Pharmacodynamic Interaction: Additive effect with CNS depressants [Source 2.5].
Timing-based interaction rules (if applicable) The tablet and chewable tablet forms of Montelukast were demonstrated to be safe and effective when administered without regard to the time of food ingestion [Source 2.4].
Population-specific interaction notes (if applicable) Use of Rupatadine is not recommended in patients with impaired kidney or liver functions due to limited clinical data [Source 3.1, 3.4]. Montelukast is noted to require no dosage adjustment in patients with mild-to-moderate hepatic insufficiency [Source 1.2].
Interaction-related restrictions Grapefruit Juice is not recommended as it can significantly increase Rupatadine exposure [Source 2.5]. Patients with aspirin sensitivity should continue to avoid Aspirin or NSAIDs [Source 2.5].

Interaction classifications (high-level)

Classification Official Regulatory Statement
Interaction severity classification (as defined in official documents) Avoided/Contraindicated: Potent CYP3A4 inhibitors (e.g., Ketoconazole) and other QTc-prolonging drugs [Source 3.1]. Cautioned: Moderate CYP3A4 inhibitors (e.g., Erythromycin) and Gemfibrozil [Source 3.3, 1.2].
Regulatory basis (EMA / FDA / etc.) Interaction profile is based on the prescribing information for both components, including FDA labeling of Montelukast and EMA/national health authority SmPC for Rupatadine [Source 2.4, 3.4].
Interaction-context constraints (as defined in official documents) Patients with known prolongation of the QT interval or cardiac arrhythmias should not receive Rupatadine [Source 3.1, 3.4].

Resulting interaction structure

The official interaction profile is defined by two primary pharmacokinetic risk domains: the CYP3A4-mediated increase in Rupatadine systemic exposure by inhibitors and the CYP2C8 pathway affecting Montelukast levels. Regulatory documents state that Gemfibrozil, a CYP2C8 inhibitor, is documented to increase Montelukast systemic exposure by approximately 4.4-fold [Source 4.4]. Co-administration with potent CYP3A4 inhibitors (e.g., Ketoconazole) is officially classified as a contraindicated combination due to the significant increase in Rupatadine concentration and the associated risk of cardiac rhythm abnormalities [Source 3.1]. Additionally, a clear pharmacodynamic caution exists regarding the additive effects of the antihistamine component with alcohol and other CNS depressants [Source 2.5].

Mechanism of Action

The mechanism of Smarti is defined by a complementary, dual-target approach that modulates signaling by both Leukotriene and Histamine/PAF mediators.


Blocking Chronic Leukotriene Pathway Activation

This mechanistic domain centers on montelukast and its function as a selective competitive antagonist at the CysLT1 receptor. By chemically blocking this critical receptor, the drug suppresses the signaling cascade initiated by Cysteinyl Leukotrienes ( LTC4, LTD4, LTE4), which are mediators responsible for smooth muscle contraction and chronic inflammatory signals. This action modulates airway smooth muscle tone and decreases inflammatory signaling in the airway walls.


Antagonizing Immediate Allergic Mediators

In the combination product (Smarti-M), this domain introduces a rapid mechanistic effect via rupatadine, which acts as an antagonist at both the Histamine H1 receptor and the Platelet-Activating Factor (PAF) receptor. This dual blockade prevents the binding of these two mediators, inhibiting the rapid activation of their respective signaling pathways. This mechanism limits mediator-induced increase in microvascular permeability and suppresses mediator-driven fluid leakage across mucosal surfaces.


Integrated Prophylactic Pathway Modulation

The combined action represents a prophylactic pathway modulation, targeting distinct yet complementary signaling systems. The two components achieve a complementary blockade of both the Leukotriene and Histamine/PAF inflammatory pathways. This upstream mechanistic intervention influences pathway activity, leading to modulation of the physiological state of airway and mucosal tissues.

Dosage and Administration Information

The drug Smarti is strictly authorized for oral administration only, supplied as film-coated tablets, chewable tablets, or oral granules. The administration protocol for chronic conditions is centered on taking a fixed dose once daily.

For most adults and adolescents aged 15 years and older, the standard daily dose of the montelukast component is 10 mg. For consistency, when the medicine is used for chronic airway management or for concurrent conditions, the dose is taken in the evening. The medicine can be taken with or without food.

Lower doses are specified for pediatric groups: children 6–14 years use 5 mg chewable tablets, and younger children use 4 mg chewable tablets or oral granules. If the oral granules are used, the contents must be administered within 15 minutes of opening the packet. The granules can be mixed with a spoonful of specific soft foods, such as applesauce or rice, or dissolved in breast milk or baby formula for immediate consumption. They must not be prepared ahead of time.

For the prevention of exercise-induced functional stress, a separate, single 10 mg dose may be taken at least two hours before exercise. If a patient takes this single, as-needed dose, they must not take another dose for at least 24 hours. The protocol for a missed daily dose is to skip the missed dose and resume the schedule at the next regular time; a double dose must never be taken. Dosage adjustments are not required for the montelukast component in patients with renal impairment or mild-to-moderate hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Compound X: Evidence Summary

Research has focused on evaluating the effects of this compound in the management of chronic pain. Evidence remains limited, and the majority of research has focused on neuropathic pain models.


Primary Clinical Trials

Neuropathic Pain

A large-scale randomized controlled trial (RCT) explored measures related to the quality of life for participants with severe neuropathic pain. The main finding reported that, compared to placebo, the group receiving the compound reported a change in the average pain score measured on the VAS scale. The study reported on secondary endpoints, which included measures related to nerve inflammation.

An open-label follow-up study collected data on adverse events over 12 months. The primary endpoint for this study was the collection of safety data, including event frequency and severity.

Chronic Back Pain

Several smaller, non-randomized studies have also investigated the compound's use in participants with non-specific chronic lower back pain. These studies were mainly focused on short-term efficacy, with the longest duration being six weeks.

The primary endpoint in most of these studies was the patient-reported average daily pain measure. Findings were inconsistent, with some studies reporting a statistically significant change in pain scores, and others reporting no significant difference compared to baseline.


Comparative Research & Combination Studies

A meta-analysis analyzed data from multiple studies comparing the compound to placebo. One of the endpoints measured was the reported duration of discomfort. No alternative treatments were assessed in this body of research.

Studies have also explored combination use with the supplement X, with researchers evaluating measures of pain and mobility compared to monotherapy. The findings from this research were preliminary and require further investigation in larger RCTs.


Safety and Tolerability

Data regarding adverse events was collected in adult participants, with findings detailed in the study appendices. The most commonly reported events included mild gastrointestinal upset and headache. Analysis of the collected safety data did not establish a relationship between the compound and serious adverse events in the included trials.

Studies in this body of evidence did not specifically focus on participants with pre-existing heart conditions.

Additional research examined the compound’s use in participants with fibromyalgia.

Frequently Asked Questions (FAQ)

Common questions about Smarti (FAQ)


Q: Is Smarti a type of antibiotic or something else?

Smarti is not an antibiotic. According to official classifications, its active ingredients are a Leukotriene Receptor Antagonist and an antihistamine. These medicines work by targeting specific inflammatory mediators in the body, which is different from how antibiotics target bacteria.


Q: How quickly does Smarti start to work?

Studies and official product information describe the medicine's onset profile, which may be rapid for certain uses. For instance, when taken for the prevention of exercise-induced functional stress, a single dose is taken at least two hours beforehand. The onset of the bronchodilation effect, as measured in clinical studies, was observed within two hours of oral administration. For chronic, daily use, the full observed benefit in studies is generally achieved after a period of consistent use.


Q: How long do the effects of Smarti typically last?

Smarti is prescribed for once-daily use because the medicine is designed to maintain consistent control throughout a 24-hour period. Studies show that the primary component's effects on the body are sustained, supporting a regular daily dosing schedule to manage chronic conditions.


Q: I'm taking vitamins, can I still take Smarti?

Official advice is to inform your doctor or pharmacist about all medicines, herbal remedies, vitamins, or any other supplements. Regulatory guidance advises this because the impact of all possible combinations, including herbal and vitamin supplements, is not fully established.


Q: Are there any specific foods I need to avoid while on Smarti?

Regulatory documents state that Grapefruit Juice is not recommended. This is because it may significantly increase the exposure of the body to the Rupatadine component of Smarti-M. Certain forms of the medicine also have specific instructions regarding when they can be taken relative to food ingestion.


Q: Why do some people say they feel tired after taking Smarti?

Drowsiness or feeling tired, which is medically referred to as somnolence, is officially listed in regulatory documents as a Common adverse reaction for the combined product. The term Common indicates that this effect was reported frequently in the clinical studies used for regulatory approval.


Q: Is 'brain fog' a known possible side effect of Smarti?

While the term 'brain fog' is not used in official labels, regulatory warnings highlight the risk of serious neuropsychiatric events. These reported events can include symptoms like attention problems and memory problems, which may be related to what some people describe as 'brain fog'.


Q: Does Smarti affect sleep patterns?

Official safety data indicates that effects on sleep are possible. Insomnia (difficulty falling or staying asleep) is listed as an Uncommon adverse reaction. Other reports related to the mental health side effect profile also include difficulty sleeping or sleepwalking.


Q: Can Smarti be split in half?

Official labeling states that non-chewable tablets are intended to be swallowed whole and not chewed. If a patient requires a specific form for ease of administration, the product is also supplied in designated chewable tablets or oral granules.


Q: Are there any known issues with Smarti and birth control pills?

Clinical studies specifically examined the interaction between the Montelukast component and oral contraceptives. These studies demonstrated that the recommended dose of Montelukast did not have a clinically important effect on how the body processes birth control pills.


Q: Is Smarti available in different strengths?

Yes, the Montelukast component is available in different strengths, typically including a 10 mg film-coated tablet for adults and adolescents, and lower doses like 5 mg or 4 mg for younger patient groups. These differences in strength and form are designed to suit various patient groups.


Q: Is Smarti available as a generic medicine?

The primary active ingredient, montelukast, is available as a generic medicine, also known as montelukast sodium. Generic availability is determined by drug regulatory authorities like the FDA.


Q: Why is Smarti not recommended for certain age groups?

Regulatory agencies specify age cut-offs for use because the safety and effectiveness of the medicine have not been established in studies for those patient groups. The combination product, for example, is not recommended for children below 12 years.


Q: How does Smarti interact with alcohol?

Official regulatory warnings advise caution regarding the combination of Smarti and alcohol. This is because the antihistamine component may have additive effects with alcohol and other CNS (central nervous system) depressants, potentially increasing sedation or dizziness.


Q: Is it normal to feel a bit dizzy when first starting Smarti?

Dizziness is officially listed in regulatory documents as a Common adverse reaction, indicating it was frequently reported in clinical studies. This classification means it is a known possible effect of the medicine.


Q: Are there non-prescription medicines that interact badly with Smarti?

Regulatory documents advise against taking Aspirin or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) if they are known to worsen asthma symptoms. Regulatory guidance suggests discussing all non-prescription medicines with a healthcare provider before starting treatment.


Q: What does the official patient information leaflet say about pregnancy and Smarti?

Official guidance emphasizes the importance of keeping asthma well-controlled during pregnancy. Treatment should be reviewed by a healthcare provider to determine the appropriate course of action during pregnancy.


Q: How often do people report feeling side effects from Smarti?

The official safety profile uses classifications like Very Common, Common, and Uncommon to categorize adverse effects based on frequency of reporting in clinical trials and post-marketing surveillance.


Q: I feel better after taking Smarti—is this the full effect or will it improve more?

The medicine's effects begin shortly after administration to modulate inflammation. However, for chronic conditions, the full benefits observed in studies are generally achieved after a period of consistent use. If the anticipated effect is not observed after a few weeks of consistent use, official guidance suggests discussing treatment options with a healthcare provider.


Q: Why is it important to tell my doctor about all my supplements when taking Smarti?

Official advice highlights that the safety of complementary and herbal medicines with this drug is not fully established. These substances are not typically tested for their effect on drug metabolism, and regulatory guidance advises discussing all supplements with your healthcare provider as a standard safety practice.

How should Smarti be stored and disposed of?

The storage and disposal of this medicine must strictly follow the conditions defined by regulatory labeling to maintain stability and ensure safety.

Requirement Official Condition
Storage Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection & Container Keep in the original package to protect from light and moisture.
Child Safety Mandatory to keep out of the sight and reach of children.
Granule Stability The oral granule mixture must be administered within 15 minutes and cannot be stored for later use.
Disposal Dispose of unused or expired product via an official drug take-back program or by mixing with an undesirable substance (e.g., coffee grounds) and placing in a sealed container in the trash, in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Smarti found in:

A-Z Index: